Continental Grain invested in a series D round that boosted the RNA technology provider's overall funding to $214m as it allocates more resources to vaccine work.

US-based agricultural and life sciences technology provider GreenLight Biosciences secured $102m yesterday in a series D round that included grain trading firm Continental Grain.

Venture capital firm Morningside Ventures led the oversubscribed round, which also featured S2G Ventures, Cormorant Asset Management, Fall Line Capital, Tao Capital Partners, Baird Capital, MLS Capital, Lupa Systems and Lewis and Clark Partners’ AgriFood fund.

GreenLight has traditionally developed RNA-based products for use in crop management and protection, but has latterly expanded into life sciences…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn